



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joseph V. BOYKIN, JR.

Serial No.: 10/716,657

Filed: November 20, 2003

)
)
)
)
)
)

Group Art No. TBA

Examiner: TBA

Docket No: 004629.00024

For: PREDICTING OUTCOME OF HYPERBARIC OXYGEN THERAPY TREATMENT
WITH NITRIC OXIDE BIOAVAILABILITY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §1.97, Applicant submits herewith Form PTO-1449, identifying information for consideration by the Examiner. A copy of the items of information is enclosed.


Applicant does not waive any rights to take appropriate action to establish patentability over the listed documents should they be applied as a reference against the claims of the present application.

Consideration of the cited information and making the same of record in the prosecution of the above-noted application are respectfully requested. Should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: 2/27/04

By: 
Susan A. Wolffe
Reg. No. 33,568

1001 G Street, N.W.
Washington, D.C. 20001-4597
(202) 824-3000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	TBA
Filing Date	November 20, 2003
First Named Inventor	Joseph V. Boykin, Jr.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	004629.00024

FEB 27 2004

TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,912,114	06-15-1999	Hutchinson et al.	
		US- 6,312,663	11-06-2001	Boykin, Jr.	
		US- 6,334,181	02-05-2002	Boykin, Jr.	
		US- 6,436,366	08-20-2002	Boykin, Jr.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Trademark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/716,657
Filing Date	November 20, 2003
First Named Inventor	Joseph V. Boykin, Jr.
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	004629.00024

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Peter LIBBY, "Atherosclerosis: The New View" Scientific American, May 2002, pp. 47-55.	
		Joseph V. BOYKIN, JR., "Letter to the Editor", Wound Repair and Regeneration, International Journal of Tissue Repair and Regeneration, September-October 2001, pp. 391-392.	
		E.B. JUDE, et al., "The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1", Diabetologia (1999), Vol. 42, pp. 748-757.	
		Stephen THOM, et al., "Stimulation of perivascular nitric oxide synthesis by oxygen", Am J Physiol Heart Circ Physiol; www.ajpheart.org, December 27, 2002, pp. H1230-H1239.	
		Joseph V. BOYKIN, JR., "The Nitric Oxide Connection: Hyperbaric Oxygen Therapy, Becaplermin, and Diabetic Ulcer Management", Journal for Prevention and Healing Advances in Wound Care; www.woundcarenet.com, July/August 2000.	
		NAVAS, et al., "Inactivation of Factor C by Dimethyl Sulfoxide Inhibits Coagulation of the Carinoscorpis Amoebocyte Lysate", Biochemistry International, Vol. 21, No. 5, August 1990, pp. 805-813.	
		Joseph V. BOYKIN, JR., "Hyperbaric Oxygen Therapy: A Physiological Approach to Selected Problem Wound Healing", WOUNDS; , Vol. 8, No. 6, November/December 1996, pp. 183-198.	
		Eman EL-SALAHY, et al., "New scope in angiogenesis: Role of vascular endothelial growth factor (VEGF), NO, lipid peroxidation, and vitamin E in the pathophysiology of pre-eclampsia among Egyptian females", Clinical Biochemistry 34, 2001, pp. 323-329.	
		Sharon O'BYRNE, et al., "Nitric Oxide Synthesis and Isoprostane Production in Subjects With Type 1 Diabetes and Normal Urinary Albumin Excretion", Diabetes, Vol. 49, May 2000, pp. 857-862.	
		Jeffrey BULGRIN, et al., "Nitric Oxide Synthesis is Suppressed in Steroid-Impaired and Diabetic Wounds", WOUNDS: A Compendium of Clinical Research and Practice, Vol. 7, No. 2, March/April 1995, pp. 48-57	
		E.P. COHEN, et al., "The Role of Nitric Oxide in Radiation Nephropathy", Archives of Physiology and Biochemistry, Vol. 104, No. 2, 1996, pp. 200-206.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/716,657
Filing Date	November 20, 2003
First Named Inventor	Joseph V. Boykin, Jr.
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	004629.00024

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Michael SCHAFFER, et al., "Nitric Oxide Regulates Wound Healing", Journal of Surgical Research 63, 1996, pp. 237-240.	
		G. A. C. MURRELL, et al., "Modulation of tendon healing by nitric oxide", Inflammation Research 46, 1997, pp. 19-27.	
		Michael SCHAFFER, et al., "Nitric Oxide Metabolism in Wounds", Journal of Surgical Research 71, 1997, pp. 25-31.	
		Stephen WILLIAMS, et al., "Impaired Nitric Oxide-Mediated Vasodilation in Patients With Non-Insulin-Dependent Diabetes Mellitus", JACC, Vol. 27, No. 3, March 1996, pp. 567-574.	
		Yasuhiro NOZAKI, et al., "Nitric oxide as an inflammatory mediator of radiation pneumonitis in rats", The American Physiological Society, 1997, pp. L651-L658.	
		Marianna HUSZKA, et al., "The Association of Reduced Endothelium Derived Relaxing Factor-No Production With Endothelial Damage and Increased in Vivo Platelet Activation in Patients with Diabetes Mellitus", Thrombosis Research, Vol. 36, No. 2, 1997, pp. 173-180.	
		Frank THORNTON, et al., "Healing in the Gastrointestinal Tract", Wound Healing, Vol. 77, No. 3, June 1977, pp. 549-573.	
		Anders ULLAND, et al., "Altered Wound Arginine Metabolism by Corticosterone and Teinoic Acid", Journal of Surgical Research 70, 1997, pp. 84-88.	
		Michael SCHAFFER, et al., "Diabetes-impaired healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation", Surgery, Vol. 121, 1997, pp. 513-519.	
		Maria CATALANO, et al., "Basal nitric oxide production is not reduced in patients with noninsulin-dependent diabetes mellitus", Vascular Medicine, Vol. 2, 1997, pp. 302-305.	
		Michael SCHAFFER, et al., "Abstract [Nitric oxide is decreased in diabetic wound healing]", Langebecks Arch Chir Suppl. Kongressbd, Vol. 114, 1997, pp. 519-521.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/716,657
Filing Date	November 20, 2003
First Named Inventor	Joseph V. Boykin, Jr.
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	004629.00024

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Liangwen SONG, et al., "The Protective Action of Taurine and L-Arginine in Radiation Pulmonary Fibrosis", Journal of Environmental Pathology, Toxicology and Oncology, Vol. 17, No. 2, 1998, pp. 151-157.	
		D. CLARENCON, et al., "Voltametric measurement of blood nitric oxide in irradiated rats", Int. J. Radiat. Biol., Vol. 75, No. 2, 1999, pp. 201-208.	
		Alexander MINCHENKO, et al., "Endothelin-1, Endothelin Receptors and eNOS Gene Transcription in Vital Organs During Traumatic Shock in Rats", Endothelium, Vol. 6, No. 4, 1999, pp. 303-314.	
		Michael SCHAFER, et al., "Lymphocyte function in wound healing and following injury", British Journal of Surgery, Vol. 85, 1998, pp. 444-460.	
		Mary BLISS, "Hyperaemia", Journal of Tissue Viability, Vol. 8, No. 4, 1998, pp. 4-13.	
		Chris BAYLIS, et al., "Measurement of nitrite and nitrate levels in plasma and urine - what does this measure tell us about the activity of the endogenous nitric oxide system?", Nephrology & Hypertension, Vol. 5, No. 29, 1998, pp. 59-62.	
		Aristidis VEVES, et al., "Endothelial Dysfunction and the Expression of Endothelial Nitric Oxide Synthetase in Diabetic Neuropathy, Vascular Disease, and Foot Ulceration", Diabetes, Vol. 47, March 1998, pp. 457-463.	
		Tsuneki SUGIHARA, et al., "Preferential Impairment of Nitric Oxide-Mediated Endothelium-Dependent Relaxation in Human Cervical Arteries After Irradiation", American Heart Association, Inc.; www.circulationaha.org, 1999, pp. 635-641.	
		William DODSON III, et al., "3-Nitrotyrosine Predicts Healing in Chronic Diabetic Foot Wounds Treated with Hyperbaric Oxygen", Clinical Research, Vol. 11, No. 6, November/December 1999, pp. 129-136.	
		David EFRON, et al., "Expression and Function of Inducible Nitric Oxide Synthase During Rat Colon Anastomotic Healing", J. Gastrointest Surg., Vol. 3, 1999, pp. 592-601.	
		Hang Ping SHI, et al., "Supplemental dietary arginine enhances wound healing in normal but not inducible nitric oxide synthase knockout mice", Surgery, Vol. 128, 2000, pp. 374-378.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/716,657
Filing Date	November 20, 2003
First Named Inventor	Joseph V. Boykin, Jr.
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	004629.00024

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author-(in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Barry CAMPBELL, et al., "Vascular endothelial growth factor attenuates trauma-induced injury in rats", British Journal of Pharmacology, Vol. 129, 2000, pp. 71-76.	
		Thomas MISKO, et al., "A Fluorometric Assay for the Measurement of Nitrite in Biological Samples", Analytical Biochemistry, Vol. 214, 1993, pp. 11-16.	
		Mary GILLIAM, et al., "A spectrophotometric Assay for Nitrate Using NADPH Oxidation by Aspergillus Nitrate Reductase", Analytical Biochemistry, Vol. 212, 1993, pp. 359-365.	
		Jeffrey BULGRIN, et al., "Arginine-free diet suppresses nitric oxide production in wounds", J. Nutr.Biochem, Vol. 4, October 1993, pp. 588-593.	
		Joseph BOYKIN, JR., et al., "Diabetes-Impaired Wound Healing Predicted by Urinary Nitrate Assay: A Preliminary, Retrospective Study", WOUNDS: A Compendium of Clinical Research and Practice, Vol. 11, No. 3, May/June 1999, pp. 62-69.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.